Anisodine Hydrobromide Tested for Acute Ischemic Stroke Treatment
Tests anisodine hydrobromide in adults with acute ischemic stroke receiving endovascular therapy.
Plain-language title generated from the registry record
Registry title: Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)
Key facts
- Where
- Anyang, Beijing, Huzhou, Jiuquan, Lishui, Shangqiu, Suzhou, Taizhou, Xuzhou, Yueqing, Yulin, Zhangzhou, and Zibo, ChinaSee the 13 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07800572, who can take part
Where in China
- Anyang People's HospitalAnyang, ChinaNot yet recruiting
- Xuanwu Hospital, Capital Medical UniversityBeijing, ChinaTaking people
- Anji County People's HospitalHuzhou, ChinaTaking people
- Jiuquan People's HospitalJiuquan, ChinaTaking people
- Lishui Central HospitalLishui, ChinaTaking people
- Shangqiu First People's HospitlShangqiu, ChinaTaking people
- Suzhou Municipal Hospital of Anhui ProvinceSuzhou, ChinaTaking people
- Taizhou Enze Medical Center (Group), Enze HospitalTaizhou, ChinaTaking people
- The affiliated hospital of xuzhou medical universityXuzhou, ChinaTaking people
- Yueqing People's HospitalYueqing, ChinaTaking people
- Yulin Second People's HospitalYulin, ChinaTaking people
- Zhangpu County HospitalZhangzhou, ChinaTaking people
- Zibo Central hospitalZibo, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Capital Medical University
- Trial code
- NCT07800572
- Record updated
- 13 October 2026
- Original description
This phase 2, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke undergoing endovascular thrombectomy.Read full original descriptionShow less
Efficacy and Safety of Anisodine Hydrobromide in Patients With Ischemic Stroke Undergoing Endovascular Treatment
This phase 2, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke undergoing endovascular thrombectomy.
Inclusion: Age 18-80 years; Anterior-circulation large-vessel occlusion involving the intracranial ICA, M1, or proximal/dominant M2; Eligible for endovascular treatment within 24 hours of last known well; Baseline NIHSS score ≥6; Baseline ASPECTS ≥6; Pre-stroke mRS score 0-1; Written informed consent provided by the participant or legally authorized representative.
Exclusion: Contraindication to anticholinergic drugs; Participation in another clinical trial within 30 days before enrollment or concurrently; Intracranial hemorrhage on baseline imaging; Significant bleeding disorder or coagulopathy; Known hypersensitivity or severe intolerance to anisodine hydrobromide; Severe arrhythmia or hemodynamic instability; Severe psychiatric disorder, dementia, or impaired consciousness precluding consent or follow-up; Malignancy or other severe systemic disease with a life expectancy <90 days; Any condition that, in the investigator's opinion, makes the patient unsuitable for study participation; Vascular anatomy unsuitable for EVT; Pregnancy, breastfeeding, or planned pregnancy within 90 days.